

**2019 surveillance – [Suspected cancer: recognition and referral \(2015\) NICE guideline NG12](#)**

**Stakeholder consultation comments form - proposal ‘not to update’**

Consultation on the proposal ‘not to update’ the guideline opens at: 9am on Thursday, 31 October 2019.

Comments on proposal to be submitted: no later than 5pm on Thursday, 14 November 2019.

<p><b>Please enter the name of your registered stakeholder or respondent organisation below.</b></p> <p>Please use this form for submitting your comments to NICE.</p> <ol style="list-style-type: none"> <li>Please put each new comment in a new row.</li> <li>Please note – we cannot accept comments forms with attachments such as research articles, letters or leaflets. If we receive forms with attachments we will return them without reading the comments. If you resubmit the comments on a form without attachments, this must be by the consultation deadline.</li> <li>If you wish to draw our attention to published studies, please supply the full reference.</li> <li>If you’re commenting for an organisation, your organisation needs to be <a href="#">registered as a stakeholder</a>.</li> </ol> <p>Not eligible? Contact the <a href="#">registered stakeholder organisation</a> that most closely represents your interests and pass your comments to them.</p> <p>We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.</p>	
<p><b>Organisation name – Stakeholder or respondent</b> (if you are commenting as an individual rather than a registered stakeholder or respondent organisation, please leave blank):</p>	<p>British Association of Dermatologists</p>
<p><b>Disclosure</b> Please disclose whether the organisation has any past or current, direct or indirect links to, or receives funding from, the tobacco industry.</p>	<p>No</p>
<p><b>Name of commentator:</b></p>	<p>Professor Nick J Levell Chair - Therapy &amp; Guidelines Sub-Committee, Executive Committee and Past President</p>

[Developing NICE guidelines: the manual](#) gives an overview of the processes used in surveillance reviews of NICE clinical guidelines.

ID	Questions	Overall response yes / no	Comments Please insert each new comment in a new row
1	Do you agree with the proposal no to update the guideline?	No	<p>You may wish to consider reviewing NG12 Suspected cancer: recognition and referral.</p> <p>There is concern in the NHS over growing numbers of skin cancer referrals. Skin cancer is now around half of all UK cancer and is doubling every 15 years. An audit of one centre showed 40% of skin cancer referrals were basal cell carcinoma, which is the commonest UK cancer and a condition not usually requiring urgent treatment. This is due to misinterpretation by GPs of NICE guidance, which allows certain high-risk basal cell carcinomas to be referred on the skin cancer pathway. Due to the large numbers involved this misinterpretation is distorting referral pathways leading to longer waits for those with urgent severe inflammatory skin disease. Therefore it would be desirable to revisit whether it is appropriate for basal cell carcinomas to be referred on the skin cancer pathway. It may be better to create a separate, urgent but not 2-week pathway, for those few basal cell carcinomas that do require seeing faster than 18 weeks.</p>
2	Do you have any comments on areas excluded from the scope of the guideline?		
3	Do you have any comments on equalities issues?		

Please email this form to: [surveillance@nice.org.uk](mailto:surveillance@nice.org.uk)

**Closing date: 5pm on Thursday, 14 November 2019**

**PLEASE NOTE:**

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, if NICE's reasonable opinion is that the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.

